Latest news with #Pachaiyappan
Business Insider
a day ago
- Business
- Business Insider
Roth MKM Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with a price target of $31.00. The company's shares closed yesterday at $13.14. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pachaiyappan is an analyst with an average return of -7.9% and a 36.71% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, Gain Therapeutics, and CervoMed. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capricor Therapeutics with a $41.50 average price target, which is a 215.83% upside from current levels. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $43.00 price target.
Business Insider
20-05-2025
- Business
- Business Insider
Roth MKM Sticks to Its Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)
In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report), with a price target of $7.00. The company's shares closed yesterday at $0.89. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pachaiyappan is an analyst with an average return of -9.8% and a 31.51% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, Gain Therapeutics, and CervoMed. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $10.00 average price target, representing a 1,023.60% upside. In a report released on May 16, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target. The company has a one-year high of $4.28 and a one-year low of $0.49. Currently, Reviva Pharmaceuticals Holdings has an average volume of 757.6K.
Business Insider
12-05-2025
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Qiagen (QGEN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research Report) and Qiagen (QGEN – Research Report). Protect Your Portfolio Against Market Uncertainty Entrada Therapeutics Inc (TRDA) Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Entrada Therapeutics Inc yesterday and set a price target of $21.00. The company's shares closed last Friday at $8.38. According to Pachaiyappan is a 1-star analyst with an average return of -6.3% and a 34.3% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Gain Therapeutics, and Verona Pharma. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Entrada Therapeutics Inc with a $24.33 average price target, a 180.6% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock. Qiagen (QGEN) In a report issued on May 8, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen, with a price target of EUR42.17. The company's shares closed last Friday at $41.86. According to Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.7% and a 33.8% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Alcon. Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $49.29, representing a 14.5% upside. In a report issued on April 24, UBS also maintained a Hold rating on the stock.
